Clinical trials: HPV Integration Site Detection
Cervical Cancers, HPV Testing
Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis
Cervical cancer is a significant health threat to women, with over 500,000 new cases and approximately 342,000 deaths worldwide annually, and about 107,000 new cases in China with 51,000 fatalities.
- Conditions
- Cervical Cancers, HPV Testing, Nanopore Sequencing, HPV Integration Site Detection
- Trial name
- NCT06644677
- Testing
- HPV integration
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
HPV Infection, Cervical Cancer
Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women
The American Society for Colposcopy and Cervical Pathology (ASCCP) recommended HPV testing or co-cytology testing as the standard primary approach for cervical cancer (CC) screening, which is highly sensitive for detection of…
- Trial name
- NCT05570331
- Testing
- HPV integration test
- Where
- China
- Volunteers
- 2,200 people
- Sponsor
- Ding Ma